Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials

Pasquale Comella, Antonio Gambardella, Giuseppe Frasci, Antonio Avallone, Raffaele Costanzo, Cesare Gridelli, Roger Stupp, Giorgio V. Scagliotti, P. Comella, G. Frasci, A. Avallone, R. Costanzo, A. Gambardella, M. Bianco, D. Bilancia, F. Buzzi, R. Bartolucci, R. Cioffi, V. Messina, P. Carnicelli & 30 others G. De Cataldis, F. Del Gaizo, S. Del Prete, L. Di Lullo, A. Farris, C. Putzu, G. Filippelli, V. Olivito, G. Dima, M. Guida, A. Iannelli, G. Condemi, S. Mancarella, L. Maiorino, M. Musicò, B. Massidda, M. T. Ionta, E. Mereu, P. Masullo, D. Muci, A. Paccagnella, N. Panza, S. Palmeri, M. Vaglica, M. Roselli, S. Mariotti, V. Milia, D. Natale, M. Ghiani, E. Barbato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (≤70 or >70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2 months), and overall survival (OS, 11.1 months versus 9.1 months) resulted slightly prolonged for younger patients. However, only stage and performance status resulted independently affecting PFS and OS. In conclusion, paclitaxel plus gemcitabine were similarly tolerated and active in younger and elderly patients. This regimen should be considered an option for the management of fit elderly patients.

Original languageEnglish
Pages (from-to)164-171
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume65
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

gemcitabine
Paclitaxel
Non-Small Cell Lung Carcinoma
Italy
Safety
Neutropenia
Disease-Free Survival
Vomiting
Anemia
Demography
Drug Therapy
Survival

Keywords

  • Elderly patients
  • Gemcitabine
  • Non-small cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. / Comella, Pasquale; Gambardella, Antonio; Frasci, Giuseppe; Avallone, Antonio; Costanzo, Raffaele; Gridelli, Cesare; Stupp, Roger; Scagliotti, Giorgio V.; Comella, P.; Frasci, G.; Avallone, A.; Costanzo, R.; Gambardella, A.; Bianco, M.; Bilancia, D.; Buzzi, F.; Bartolucci, R.; Cioffi, R.; Messina, V.; Carnicelli, P.; De Cataldis, G.; Del Gaizo, F.; Del Prete, S.; Di Lullo, L.; Farris, A.; Putzu, C.; Filippelli, G.; Olivito, V.; Dima, G.; Guida, M.; Iannelli, A.; Condemi, G.; Mancarella, S.; Maiorino, L.; Musicò, M.; Massidda, B.; Ionta, M. T.; Mereu, E.; Masullo, P.; Muci, D.; Paccagnella, A.; Panza, N.; Palmeri, S.; Vaglica, M.; Roselli, M.; Mariotti, S.; Milia, V.; Natale, D.; Ghiani, M.; Barbato, E.

In: Critical Reviews in Oncology/Hematology, Vol. 65, No. 2, 02.2008, p. 164-171.

Research output: Contribution to journalArticle

Comella, P, Gambardella, A, Frasci, G, Avallone, A, Costanzo, R, Gridelli, C, Stupp, R, Scagliotti, GV, Comella, P, Frasci, G, Avallone, A, Costanzo, R, Gambardella, A, Bianco, M, Bilancia, D, Buzzi, F, Bartolucci, R, Cioffi, R, Messina, V, Carnicelli, P, De Cataldis, G, Del Gaizo, F, Del Prete, S, Di Lullo, L, Farris, A, Putzu, C, Filippelli, G, Olivito, V, Dima, G, Guida, M, Iannelli, A, Condemi, G, Mancarella, S, Maiorino, L, Musicò, M, Massidda, B, Ionta, MT, Mereu, E, Masullo, P, Muci, D, Paccagnella, A, Panza, N, Palmeri, S, Vaglica, M, Roselli, M, Mariotti, S, Milia, V, Natale, D, Ghiani, M & Barbato, E 2008, 'Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials', Critical Reviews in Oncology/Hematology, vol. 65, no. 2, pp. 164-171. https://doi.org/10.1016/j.critrevonc.2007.06.014
Comella, Pasquale ; Gambardella, Antonio ; Frasci, Giuseppe ; Avallone, Antonio ; Costanzo, Raffaele ; Gridelli, Cesare ; Stupp, Roger ; Scagliotti, Giorgio V. ; Comella, P. ; Frasci, G. ; Avallone, A. ; Costanzo, R. ; Gambardella, A. ; Bianco, M. ; Bilancia, D. ; Buzzi, F. ; Bartolucci, R. ; Cioffi, R. ; Messina, V. ; Carnicelli, P. ; De Cataldis, G. ; Del Gaizo, F. ; Del Prete, S. ; Di Lullo, L. ; Farris, A. ; Putzu, C. ; Filippelli, G. ; Olivito, V. ; Dima, G. ; Guida, M. ; Iannelli, A. ; Condemi, G. ; Mancarella, S. ; Maiorino, L. ; Musicò, M. ; Massidda, B. ; Ionta, M. T. ; Mereu, E. ; Masullo, P. ; Muci, D. ; Paccagnella, A. ; Panza, N. ; Palmeri, S. ; Vaglica, M. ; Roselli, M. ; Mariotti, S. ; Milia, V. ; Natale, D. ; Ghiani, M. ; Barbato, E. / Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. In: Critical Reviews in Oncology/Hematology. 2008 ; Vol. 65, No. 2. pp. 164-171.
@article{5aa56848838342af8e594adc8dcac934,
title = "Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials",
abstract = "We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (≤70 or >70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36{\%} versus 30{\%}). Chemotherapy was well tolerated, but severe neutropenia (12{\%} versus 7{\%}), anaemia (6.6{\%} versus 1.8{\%}), and vomiting (5{\%} versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2 months), and overall survival (OS, 11.1 months versus 9.1 months) resulted slightly prolonged for younger patients. However, only stage and performance status resulted independently affecting PFS and OS. In conclusion, paclitaxel plus gemcitabine were similarly tolerated and active in younger and elderly patients. This regimen should be considered an option for the management of fit elderly patients.",
keywords = "Elderly patients, Gemcitabine, Non-small cell lung cancer, Paclitaxel",
author = "Pasquale Comella and Antonio Gambardella and Giuseppe Frasci and Antonio Avallone and Raffaele Costanzo and Cesare Gridelli and Roger Stupp and Scagliotti, {Giorgio V.} and P. Comella and G. Frasci and A. Avallone and R. Costanzo and A. Gambardella and M. Bianco and D. Bilancia and F. Buzzi and R. Bartolucci and R. Cioffi and V. Messina and P. Carnicelli and {De Cataldis}, G. and {Del Gaizo}, F. and {Del Prete}, S. and {Di Lullo}, L. and A. Farris and C. Putzu and G. Filippelli and V. Olivito and G. Dima and M. Guida and A. Iannelli and G. Condemi and S. Mancarella and L. Maiorino and M. Music{\`o} and B. Massidda and Ionta, {M. T.} and E. Mereu and P. Masullo and D. Muci and A. Paccagnella and N. Panza and S. Palmeri and M. Vaglica and M. Roselli and S. Mariotti and V. Milia and D. Natale and M. Ghiani and E. Barbato",
year = "2008",
month = "2",
doi = "10.1016/j.critrevonc.2007.06.014",
language = "English",
volume = "65",
pages = "164--171",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials

AU - Comella, Pasquale

AU - Gambardella, Antonio

AU - Frasci, Giuseppe

AU - Avallone, Antonio

AU - Costanzo, Raffaele

AU - Gridelli, Cesare

AU - Stupp, Roger

AU - Scagliotti, Giorgio V.

AU - Comella, P.

AU - Frasci, G.

AU - Avallone, A.

AU - Costanzo, R.

AU - Gambardella, A.

AU - Bianco, M.

AU - Bilancia, D.

AU - Buzzi, F.

AU - Bartolucci, R.

AU - Cioffi, R.

AU - Messina, V.

AU - Carnicelli, P.

AU - De Cataldis, G.

AU - Del Gaizo, F.

AU - Del Prete, S.

AU - Di Lullo, L.

AU - Farris, A.

AU - Putzu, C.

AU - Filippelli, G.

AU - Olivito, V.

AU - Dima, G.

AU - Guida, M.

AU - Iannelli, A.

AU - Condemi, G.

AU - Mancarella, S.

AU - Maiorino, L.

AU - Musicò, M.

AU - Massidda, B.

AU - Ionta, M. T.

AU - Mereu, E.

AU - Masullo, P.

AU - Muci, D.

AU - Paccagnella, A.

AU - Panza, N.

AU - Palmeri, S.

AU - Vaglica, M.

AU - Roselli, M.

AU - Mariotti, S.

AU - Milia, V.

AU - Natale, D.

AU - Ghiani, M.

AU - Barbato, E.

PY - 2008/2

Y1 - 2008/2

N2 - We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (≤70 or >70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2 months), and overall survival (OS, 11.1 months versus 9.1 months) resulted slightly prolonged for younger patients. However, only stage and performance status resulted independently affecting PFS and OS. In conclusion, paclitaxel plus gemcitabine were similarly tolerated and active in younger and elderly patients. This regimen should be considered an option for the management of fit elderly patients.

AB - We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (≤70 or >70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2 months), and overall survival (OS, 11.1 months versus 9.1 months) resulted slightly prolonged for younger patients. However, only stage and performance status resulted independently affecting PFS and OS. In conclusion, paclitaxel plus gemcitabine were similarly tolerated and active in younger and elderly patients. This regimen should be considered an option for the management of fit elderly patients.

KW - Elderly patients

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=37549005200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549005200&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.06.014

DO - 10.1016/j.critrevonc.2007.06.014

M3 - Article

VL - 65

SP - 164

EP - 171

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -